Next Article in Journal
The Role of Gut Microbiota and Its Produced Metabolites in Obesity, Dyslipidemia, Adipocyte Dysfunction, and Its Interventions
Next Article in Special Issue
Lipid Profiling in Cancer Diagnosis with Hand-Held Ambient Mass Spectrometry Probes: Addressing the Late-Stage Performance Concerns
Previous Article in Journal
Combining HPLC-DAD-QTOF-MS and HPLC-SPE-NMR to Monitor In Vitro Vitetrifolin D Phase I and II Metabolism
Previous Article in Special Issue
Lipoprotein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Metabolites
Volume 11
Issue 8
10.3390/metabo11080530
Review Report
metabolites-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Do Mass Spectrometry-Derived Metabolomics Improve the Prediction of Pregnancy-Related Disorders? Findings from a UK Birth Cohort with Independent Validation

Metabolites 2021, 11(8), 530; https://doi.org/10.3390/metabo11080530
by Nancy McBride 1,2,3,*, Paul Yousefi 1,3, Ulla Sovio 4, Kurt Taylor 1, Yassaman Vafai 5, Tiffany Yang 5, Bo Hou 5, Matthew Suderman 1,3, Caroline Relton 1,3, Gordon C. S. Smith 4 and Deborah A. Lawlor 1,2,3
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Metabolites 2021, 11(8), 530; https://doi.org/10.3390/metabo11080530
Submission received: 16 June 2021 / Revised: 23 July 2021 / Accepted: 30 July 2021 / Published: 10 August 2021
(This article belongs to the Special Issue Metabolomics of Complex Traits II)

Round 1

Reviewer 1 Report

The article entitled “Do mass-spectrometry-derived metabolomics improve prediction of pregnancy-related disorders?” is an important finding. In this article, the authors are assessing risk factors based on clinical parameters of the cohorts and the expression of metabolites. It is an important finding, and the manuscript is well-written. Despite mentioning how metabolites are combined to analyze the risk factors, nothing much is mention about the expression levels of different metabolites in different groups.  Incorporating the expression levels of each metabolite in the groups and what made them select only a few metabolites are not well explained. Also, examining the hazard ratio after combining metabolites with the maternal risk factors will shed more light.

Author Response

Please see the attachment. 

Author Response File: Author Response.pdf

Reviewer 2 Report

The authors use metabolites information to pregnancy-related disorders. They demonstrated the ability of metabolomics to diagnose diseases with an elastic net penalized regression. In order to let readers understand the analysis process more clearly. I suggest the authors explain how to optimize the hyperparameters and impute the missing values. 

How to find the ratio of the product of the plasmalogen 1-(1-enyl-stearoyl)-2-oleoyl-GPC (P-18:0/18:1) and the steroid 5α-androstan-3α,17α-diol disulfate to the product of the carbohydrate 1,5-anhydroglucitol and the polyamine N1,N12-diacetylspermine was a better predictor is quite interesting. However, the authors did not mention how to identify the potential predictors/biomarkers.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

N/A

Back to TopTop